Full Press Release Details
Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth
Conference on October 21
is pursuing high value opportunities in a massive healthcare market with no known competing FDA-approved drugs for treating aging disorders
and extending healthy lifespan
MD. - October 19, 2021 - MyMD Pharmaceuticals, Inc. (Nasdaq:
MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to extending healthy lifespan,
announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021,
at 4:30 p.m. ET in Track 1. The conference is being held at the Wyndham Grand Jupiter at Harbourside Place in Jupiter, Florida.
Chief Scientific Officer Adam Kaplin, M.D., Ph.D. will discuss the multiple indications for each of MyMD's novel drug candidates,
MYMD-1 and Supera-CBD. A webcast of the presentation will be available live and on demand for 90 days after the conference.
primary purpose is to slow the aging process and extend healthy lifespan, and it is also showing promise as a potential treatment for
post- COVID-19 complications and as an anti-fibrotic and anti-prolific therapeutic. MYMD-1 has shown effectiveness in regulating the
immune system by performing as a selective inhibitor of tumor necrosis factor-alpha (TNF- ), a driver of chronic inflammation.
Unlike other therapies, MYMD-1 has been shown to selectively block TNF- when it becomes overactivated in autoimmune diseases and
cytokine storms, but not block it from doing its normal job of being a first responder to any routine type of moderate infection. MYMD-1's
ease of oral dosing is another differentiator compared to currently available TNF- blockers, all of which require delivery by
injection or infusion. No approved TNF inhibitor has ever been dosed orally. In addition, the drug is not immunosuppressive and has not
been shown to cause the serious side effects common with traditional therapies that treat inflammation. MyMD expects to launch two Phase
2 trials during the current quarter for MYMD-1 - one for delaying aging and prolonging healthy lifespan, and the other for post-
COVID-19 depression and cytokine elevation.
is MyMD's pre-clinical patented synthetic cannabidiol (CBD) derivative that is being developed as a pharmaceutical drug to address
anxiety, pain, and neurodegeneration. Supera-CBD targets the cannabinoid receptor type 2 (CB2), a protein mainly expressed in the immune
system and which is associated with the therapeutic effects of CBD, including its anxiolytic, anticonvulsant, antipsychotic, neuroprotective
and anti-inflammatory properties. CB2 receptors do not create an intoxicating negative psychotropic reaction (e.g. a high). In contrast,
CB1 is usually expressed in the brain and distributed throughout the central nervous system to deliver an intoxicating effect. A vast
majority of CBD developers are pursuing compounds targeted to CB2 that have minimal CB1 affinity. MyMD's Supera-CBD, with low CB1
affinity and four-fold increased CB2 binding, is 8,000 times more potent a CB2 agonist (activator) than regular CBD. The Company believes
that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy,
followed by chronic pain.
MyMD Pharmaceuticals, Inc.
Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on
developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. MYMD-1 is a drug
platform based on a clinical stage small molecule that regulates the immune system to control TNF- , which drives chronic inflammation,
and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune
diseases and COVID-19- associated depression. The Company's second drug platform, Supera-CBD, is being developed to treat chronic
pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve
upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more
information, visit www.mymd.com.
Statement Regarding Forward-Looking Statements
press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties
and other factors which may cause actual results, performance or achievements to be materially different from any expected future results,
performance, or achievements. Forward-looking statements speak only as of the date they are made and none of MyMD nor its affiliates
assume any duty to update forward-looking statements. Words such as "anticipate," "believe," "could,"
"estimate," "expect," "may," "plan," "will," "would'' and
other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results
to differ materially from those indicated by such forward-looking statements include, without limitation: the timing of, and MyMD's
ability to, obtain and maintain regulatory approvals for clinical trials of MyMD's pharmaceutical candidates; the timing and results
of MyMD's planned clinical trials for its pharmaceutical candidates; the amount of funds MyMD requires for its pharmaceutical candidates;
increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which MyMD operates;
MyMD's ability to retain and attract senior management and other key employees; MyMD's ability to quickly and effectively
respond to new technological developments; MyMD's ability to protect its trade secrets or other proprietary rights, operate without
infringing upon the proprietary rights of others and prevent others from infringing on MyMD's proprietary rights; and the impact
of the ongoing COVID-19 pandemic on MyMD's results of operations, business plan and the global economy. A discussion of these and
other factors with respect to MyMD is set forth in the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021, filed
by MyMD on August 16, 2021. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation
to revise any forward-looking statements, whether as a result of new information, future events or otherwise.